Antimigraine efficacy of telcagepant based on patient's historical triptan response

Headache

Volumn 51, Issue 1, 2011, Pages 64-72

  Ho, Tony W ^a   Olesen, Jes ^b   Dodick, David W ^c   Kost, James ^a   Lines, Christopher ^a   Ferrari, Michel D ^d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c MAYO CLINIC   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CGRP; efficacy; migraine; telcagepant; zolmitriptan

Indexed keywords

PLACEBO; TELCAGEPANT; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ADULT; ANALGESIA; ARTICLE; ASTHENIA; CHEST TIGHTNESS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSESTHESIA; FATIGUE; FEMALE; HUMAN; HYPERESTHESIA; HYPESTHESIA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NAUSEA; OUTPATIENT CARE; PARESTHESIA; POST HOC ANALYSIS; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF REPORT; SOMNOLENCE; THORAX PAIN; TREATMENT RESPONSE; XEROSTOMIA;

EID: 78650938657     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2010.01790.x     Document Type: Article

References (18)

1. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008; 70: 1304-1312.
2. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008; 372: 2115-2123.
3. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ,. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet. 2001; 358: 1668-1675.
4. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB,. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002; 22: 633-658.
5. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24 (Suppl. 1): 9-160.
6. Goldstein J, Tiseo PJ, Albert KS, Li C, Sykes CR,. Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. Headache. 2006; 46: 1142-1150.
7. Färkkilä M, Olesen J, Dahlöf C, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia. 2003; 23: 463-471.
8. Mathew NT, Kailasam J, Gentry P, Chernyshev O,. Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: A comparative open trial. Headache. 2000; 40: 464-465.
9. Stark SR, Spierings EL, McNeal S, Putnam DG, Bolden-Watson CP, O'Quinn S,. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache. 2000; 40: 513-520.
10. Diener HC, Gendolla A, Gebert I, Beneke M,. Almotriptan in migraine patients who respond poorly to oral sumatriptan: A double-blind, randomized trial. Eur Neurol. 2005; 53 (Suppl. 1): 41-48. (Pubitemid 40827685)
11. Dodick DW,. Triptan nonresponder studies: Implications for clinical practice. Headache. 2005; 45: 162.
12. Sheftell FD, Feleppa M, Tepper S, Volcy M, Rapoport AM, Bigal ME,. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache. 2004; 44: 668.
13. Diener HC, Ferrari M, Mansbach H,. SNAP Database Study Group. Predicting the response to sumatriptan: The Sumatriptan Naratriptan Aggragate Patient Database. Neurology. 2004; 63: 524.
14. Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Almas M, Parsons B,. Identification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database. Cephalalgia. 2008; 28: 35-40.
15. Mehrotra S, Vanmolkot KR, Frants RR, van den Maagdenberg AM, Ferrari MD, MaassenVanDenBrink A,. The phe-124-Cys and A-161T variants of the human 5-HT1B receptor gene are not major determinants of the clinical response to sumatriptan. Headache. 2007; 47: 711-716.
16. Velati D, Viana M, Cresta S, et al. 5-hydroxytryptamine1B receptor and triptan response in migraine, lack of association with common polymorphisms. Eur J Pharmacol. 2008; 580: 43-47.
17. Salvatore CA, Hershey JC, Corcoran HA, et al. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2- trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-car-boxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther. 2008; 324: 416-421.
18. Connor KM, Shapiro RE, Diener H-C, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009; 73: 970-977.